secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095059
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics Q2 net loss $34.7M; cash $179.8M; clinical milestones for SMARCA2 and CDK9 programs
--------------------------------------------------------------------------------

- Net loss $34.7M ($0.46/share) vs $30.4M ($0.54/share) in Q2 2023; R&D expense rose to $29.5M from $25.0M.
- Cash, equivalents and marketable securities $179.8M at June 30, 2024; runway extended into 2026.
- PRT3789 interim Phase 1 data selected for oral presentation at ESMO Congress 2024 (Sept 13).
- IND authorized for oral SMARCA2 degrader PRT7732; Phase 1 start expected H2 2024.
- Clinical collaboration with Merck to evaluate PRT3789 in combination with KEYTRUDA; Phase 2 start expected Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024095059/0000950170-24-095059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024095059/prld-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer